A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

Summary

The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.

Timeline

Start

2014-10

Primary completion

2017-09-20

Completion

2017-09-20

Outcome

Missed primary endpoint

registry analysis (superiority test); Napabucasin + Paclitaxel vs Placebo + Paclitaxel; p = 0.8596; Hazard Ratio (HR) 1.01 (95% CI 0.86 to 1.02); Log Rank; note: two-sided NCT02178956 ↗

Drugs

Indications